Alban Longchamp, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydrogen Sulfide | 11 | 2022 | 137 | 2.410 |
Why?
|
| Reperfusion Injury | 7 | 2024 | 1025 | 2.230 |
Why?
|
| Tunica Intima | 6 | 2021 | 464 | 1.750 |
Why?
|
| Kidney Transplantation | 5 | 2023 | 4246 | 0.950 |
Why?
|
| Hyperplasia | 6 | 2022 | 1183 | 0.820 |
Why?
|
| Activating Transcription Factor 4 | 2 | 2022 | 81 | 0.820 |
Why?
|
| Saphenous Vein | 3 | 2018 | 531 | 0.800 |
Why?
|
| Veins | 5 | 2021 | 769 | 0.760 |
Why?
|
| Perfusion | 4 | 2023 | 1359 | 0.750 |
Why?
|
| Warm Ischemia | 1 | 2019 | 53 | 0.710 |
Why?
|
| Aneurysm, False | 1 | 2022 | 276 | 0.710 |
Why?
|
| Kidney | 5 | 2023 | 7167 | 0.660 |
Why?
|
| Amino Acids, Sulfur | 1 | 2018 | 16 | 0.650 |
Why?
|
| Fibroblast Growth Factors | 1 | 2024 | 879 | 0.620 |
Why?
|
| Diet, Protein-Restricted | 4 | 2020 | 71 | 0.620 |
Why?
|
| Vascular Grafting | 2 | 2019 | 142 | 0.620 |
Why?
|
| Aortic Aneurysm | 1 | 2022 | 643 | 0.610 |
Why?
|
| Connexin 43 | 1 | 2015 | 206 | 0.490 |
Why?
|
| Hypothermia, Induced | 1 | 2019 | 747 | 0.490 |
Why?
|
| Adenosine Triphosphate | 1 | 2020 | 2024 | 0.470 |
Why?
|
| Hydrogels | 1 | 2019 | 723 | 0.470 |
Why?
|
| Cystathionine gamma-Lyase | 5 | 2022 | 36 | 0.470 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2022 | 1384 | 0.430 |
Why?
|
| Liver Transplantation | 1 | 2023 | 2117 | 0.420 |
Why?
|
| Surgical Procedures, Operative | 1 | 2024 | 1873 | 0.410 |
Why?
|
| Preoperative Care | 3 | 2018 | 2245 | 0.410 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2022 | 3760 | 0.390 |
Why?
|
| Fasting | 1 | 2017 | 1589 | 0.370 |
Why?
|
| Endovascular Procedures | 1 | 2022 | 1973 | 0.330 |
Why?
|
| Critical Illness | 2 | 2020 | 2665 | 0.320 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2018 | 3502 | 0.310 |
Why?
|
| Peptides | 1 | 2019 | 4392 | 0.290 |
Why?
|
| Caloric Restriction | 4 | 2022 | 302 | 0.290 |
Why?
|
| Tissue Scaffolds | 1 | 2014 | 957 | 0.290 |
Why?
|
| Liver | 7 | 2024 | 7470 | 0.290 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2020 | 548 | 0.270 |
Why?
|
| Carotid Stenosis | 3 | 2021 | 854 | 0.270 |
Why?
|
| Dietary Carbohydrates | 2 | 2024 | 904 | 0.270 |
Why?
|
| Ischemia | 3 | 2019 | 1911 | 0.260 |
Why?
|
| Swine | 4 | 2022 | 5934 | 0.230 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3130 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3236 | 0.210 |
Why?
|
| Methionine | 3 | 2022 | 590 | 0.210 |
Why?
|
| Animals | 23 | 2024 | 168561 | 0.210 |
Why?
|
| Dietary Proteins | 2 | 2024 | 963 | 0.200 |
Why?
|
| Phosphorus | 1 | 2022 | 338 | 0.200 |
Why?
|
| Glycerol | 1 | 2022 | 278 | 0.200 |
Why?
|
| Captopril | 1 | 2021 | 272 | 0.190 |
Why?
|
| Myocytes, Smooth Muscle | 4 | 2022 | 686 | 0.190 |
Why?
|
| Organ Preservation | 1 | 2023 | 324 | 0.190 |
Why?
|
| Hemorrhoids | 1 | 2020 | 20 | 0.190 |
Why?
|
| Pandemics | 1 | 2020 | 8328 | 0.180 |
Why?
|
| Transplants | 1 | 2022 | 208 | 0.180 |
Why?
|
| Abdominal Cavity | 1 | 2019 | 44 | 0.180 |
Why?
|
| Malaria, Cerebral | 1 | 2021 | 135 | 0.180 |
Why?
|
| Adiponectin | 2 | 2016 | 1099 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 7 | 2024 | 21821 | 0.170 |
Why?
|
| Versicans | 1 | 2018 | 33 | 0.170 |
Why?
|
| Sirtuin 1 | 2 | 2018 | 244 | 0.170 |
Why?
|
| Niacinamide | 1 | 2021 | 416 | 0.160 |
Why?
|
| Parasites | 1 | 2021 | 161 | 0.160 |
Why?
|
| Neointima | 2 | 2020 | 135 | 0.160 |
Why?
|
| Urine | 1 | 2019 | 370 | 0.160 |
Why?
|
| Reperfusion | 1 | 2019 | 284 | 0.150 |
Why?
|
| Lipoproteins, VLDL | 1 | 2018 | 201 | 0.150 |
Why?
|
| Physical Conditioning, Animal | 2 | 2018 | 362 | 0.150 |
Why?
|
| Vena Cava, Inferior | 1 | 2020 | 436 | 0.140 |
Why?
|
| Body Temperature | 1 | 2019 | 776 | 0.140 |
Why?
|
| Tissue Donors | 2 | 2022 | 2205 | 0.140 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2019 | 555 | 0.130 |
Why?
|
| Antibody Formation | 1 | 2020 | 1402 | 0.130 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2022 | 849 | 0.130 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 18006 | 0.130 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2017 | 370 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 1517 | 0.130 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2016 | 215 | 0.120 |
Why?
|
| Aorta | 1 | 2022 | 2057 | 0.120 |
Why?
|
| Mice | 11 | 2024 | 81045 | 0.120 |
Why?
|
| Postoperative Period | 1 | 2019 | 1839 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2022 | 1178 | 0.120 |
Why?
|
| Cryopreservation | 1 | 2019 | 664 | 0.120 |
Why?
|
| Humans | 27 | 2024 | 742088 | 0.120 |
Why?
|
| NAD | 1 | 2018 | 594 | 0.120 |
Why?
|
| Ephrin-B2 | 1 | 2014 | 39 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 627 | 0.120 |
Why?
|
| Arteries | 1 | 2019 | 1118 | 0.120 |
Why?
|
| Longevity | 1 | 2022 | 1069 | 0.120 |
Why?
|
| Receptor, EphB4 | 1 | 2014 | 38 | 0.120 |
Why?
|
| Neovascularization, Physiologic | 2 | 2018 | 1350 | 0.120 |
Why?
|
| Muscle Contraction | 1 | 2019 | 1241 | 0.120 |
Why?
|
| Lower Extremity | 2 | 2019 | 1151 | 0.120 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2014 | 171 | 0.110 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2017 | 608 | 0.110 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2017 | 703 | 0.110 |
Why?
|
| Models, Animal | 1 | 2019 | 2170 | 0.110 |
Why?
|
| Polyesters | 1 | 2014 | 363 | 0.110 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2014 | 281 | 0.110 |
Why?
|
| Surgical Mesh | 1 | 2014 | 256 | 0.110 |
Why?
|
| RNA Interference | 2 | 2018 | 2890 | 0.110 |
Why?
|
| Stress, Physiological | 2 | 2017 | 1402 | 0.100 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 3504 | 0.100 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2014 | 472 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2014 | 759 | 0.100 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2014 | 277 | 0.100 |
Why?
|
| Subcutaneous Fat | 1 | 2014 | 391 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2014 | 689 | 0.100 |
Why?
|
| Triglycerides | 1 | 2018 | 2450 | 0.090 |
Why?
|
| Stents | 1 | 2022 | 3276 | 0.090 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 638 | 0.090 |
Why?
|
| Pressure | 1 | 2014 | 1203 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2017 | 1119 | 0.090 |
Why?
|
| Glucose | 1 | 2022 | 4391 | 0.090 |
Why?
|
| Endarterectomy, Carotid | 1 | 2015 | 546 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2018 | 1368 | 0.090 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 2187 | 0.090 |
Why?
|
| Rabbits | 1 | 2015 | 4886 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2015 | 1504 | 0.080 |
Why?
|
| Stress, Mechanical | 1 | 2014 | 1684 | 0.080 |
Why?
|
| Male | 16 | 2024 | 349538 | 0.080 |
Why?
|
| Aging | 2 | 2018 | 8626 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 1967 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2021 | 4393 | 0.080 |
Why?
|
| Wound Healing | 1 | 2018 | 2781 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 2107 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2016 | 1473 | 0.070 |
Why?
|
| Vascular Patency | 2 | 2020 | 885 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 2195 | 0.070 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 1538 | 0.070 |
Why?
|
| Animals, Genetically Modified | 2 | 2022 | 1546 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2014 | 3001 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 2006 | 0.070 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 1184 | 0.060 |
Why?
|
| Female | 11 | 2024 | 379592 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2014 | 1780 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2022 | 10472 | 0.060 |
Why?
|
| Transplantation, Heterologous | 2 | 2022 | 2382 | 0.060 |
Why?
|
| Rats | 1 | 2019 | 24265 | 0.050 |
Why?
|
| Mice, Knockout | 4 | 2020 | 14554 | 0.050 |
Why?
|
| Thiosulfates | 1 | 2022 | 52 | 0.050 |
Why?
|
| Insulin | 1 | 2017 | 6575 | 0.050 |
Why?
|
| Aged | 6 | 2023 | 162944 | 0.050 |
Why?
|
| Hypertension | 1 | 2021 | 8455 | 0.050 |
Why?
|
| Gluconeogenesis | 1 | 2022 | 183 | 0.050 |
Why?
|
| Radiation, Ionizing | 1 | 2022 | 258 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2022 | 62966 | 0.050 |
Why?
|
| Pyridinium Compounds | 1 | 2021 | 84 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2022 | 574 | 0.040 |
Why?
|
| Caenorhabditis elegans | 2 | 2022 | 1416 | 0.040 |
Why?
|
| Primates | 1 | 2022 | 543 | 0.040 |
Why?
|
| Cholesterol, Dietary | 1 | 2020 | 231 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 2020 | 475 | 0.040 |
Why?
|
| Organ Culture Techniques | 1 | 2021 | 808 | 0.040 |
Why?
|
| Carotid Artery, Common | 1 | 2020 | 183 | 0.040 |
Why?
|
| Vasa Vasorum | 1 | 2018 | 26 | 0.040 |
Why?
|
| Serine | 1 | 2022 | 828 | 0.040 |
Why?
|
| Tunica Media | 1 | 2018 | 113 | 0.040 |
Why?
|
| Tubulin | 1 | 2022 | 695 | 0.040 |
Why?
|
| Dextrothyroxine | 1 | 2017 | 6 | 0.040 |
Why?
|
| Hydrolysis | 1 | 2018 | 682 | 0.040 |
Why?
|
| Receptors, LDL | 1 | 2020 | 475 | 0.040 |
Why?
|
| Tissue Culture Techniques | 1 | 2018 | 291 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2021 | 952 | 0.040 |
Why?
|
| Glutamic Acid | 1 | 2022 | 1167 | 0.040 |
Why?
|
| Adipose Tissue | 2 | 2021 | 3278 | 0.040 |
Why?
|
| Limb Salvage | 1 | 2019 | 433 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2018 | 657 | 0.040 |
Why?
|
| Diet | 1 | 2014 | 7923 | 0.040 |
Why?
|
| Apolipoproteins | 1 | 2018 | 315 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2018 | 514 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 57683 | 0.030 |
Why?
|
| Hypertriglyceridemia | 1 | 2018 | 293 | 0.030 |
Why?
|
| Time Factors | 4 | 2020 | 40054 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2014 | 19 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 2018 | 489 | 0.030 |
Why?
|
| Cisplatin | 1 | 2021 | 1637 | 0.030 |
Why?
|
| Growth Hormone | 1 | 2017 | 703 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2021 | 19223 | 0.030 |
Why?
|
| Yeasts | 1 | 2014 | 285 | 0.030 |
Why?
|
| Paracrine Communication | 1 | 2015 | 276 | 0.030 |
Why?
|
| Microvessels | 1 | 2018 | 544 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2014 | 642 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2018 | 739 | 0.030 |
Why?
|
| Leptin | 1 | 2021 | 1593 | 0.030 |
Why?
|
| Stroke | 1 | 2015 | 9963 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2018 | 1121 | 0.030 |
Why?
|
| Urea | 1 | 2014 | 449 | 0.030 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2014 | 364 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2022 | 2941 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2020 | 1606 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2022 | 23387 | 0.020 |
Why?
|
| Graft Survival | 1 | 2021 | 3733 | 0.020 |
Why?
|
| Middle Aged | 5 | 2019 | 213127 | 0.020 |
Why?
|
| Cysteine | 1 | 2014 | 873 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 1887 | 0.020 |
Why?
|
| Risk Factors | 4 | 2019 | 72145 | 0.020 |
Why?
|
| Reoperation | 1 | 2019 | 4200 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2022 | 3294 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 2014 | 0.020 |
Why?
|
| Biological Evolution | 1 | 2014 | 1074 | 0.020 |
Why?
|
| Creatinine | 1 | 2014 | 1916 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2014 | 2615 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2014 | 1183 | 0.020 |
Why?
|
| Energy Intake | 1 | 2014 | 2147 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2021 | 8541 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2014 | 1704 | 0.020 |
Why?
|
| Stem Cells | 1 | 2018 | 3563 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2018 | 3455 | 0.020 |
Why?
|
| Mitochondria | 1 | 2018 | 3520 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 11363 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 19862 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2014 | 4197 | 0.010 |
Why?
|
| Disease Progression | 1 | 2021 | 13256 | 0.010 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2015 | 1499 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 4933 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15530 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 9941 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2021 | 77098 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2015 | 53187 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 13655 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 16331 | 0.010 |
Why?
|
| United States | 1 | 2022 | 69693 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2016 | 40450 | 0.010 |
Why?
|
| Child | 1 | 2021 | 77478 | 0.010 |
Why?
|
| Adult | 1 | 2019 | 213712 | 0.000 |
Why?
|